Skip to content

Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice

May 25, 2023


PARP inhibitor maintenance therapy (mPARPi) is a common treatment for patients with newly diagnosed advanced ovarian cancer following surgery and platinum chemotherapy. Clinical trials have shown that mPARPi can benefit patients with and without BRCA1/2 mutations. However, it is unclear how effective mPARPi is for patients who do not have specific biomarkers without homologous recombination deficiency (HRD). Using the Flatiron Health-Foundation Medicine Clinico-Genomic Database, this study aimed to compare the effectiveness of mPARPi in real-world practice based on two biomarkers: BRCA1/2 mutation and/or a novel biomarker called HRD signature (HRDsig). 

Why this matters

By comparing the outcomes of ovarian cancer patients with and without BRCA1/2 mutations and HRDsig, this study aims to determine the effectiveness of mPARPi in real-world clinical practice. This information can help clinicians better understand which patients are most likely to benefit from this treatment and make more informed decisions about treatment options. 

Read the research